Drug therapy: Prevention and treatment of major blood loss

被引：323

作者：

Mannucci, Pier Mannuccio

Levi, Marcel

机构：

[1] Univ Milan, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, I-20122 Milan, Italy

[2] Univ Milan, Dept Med & Med Specialties, I-20122 Milan, Italy

[3] Maggiore Hosp, Ist Ric & Cura Carattere Sci, Milan, Italy

[4] Mangiagalli & Regina Elena Fdn, Milan, Italy

[5] Univ Amsterdam, Acad Med Ctr, Dept Med & Vasc Med, NL-1105 AZ Amsterdam, Netherlands

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2007年 / 356卷 / 22期

关键词：

D O I：

10.1056/NEJMra067742

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2301 / 2311

页数：11

共 103 条

[61] Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding:: A systematic review [J].

Levi, M ;

Peters, M ;

Büller, HR .

CRITICAL CARE MEDICINE, 2005, 33 (04) :883-890

[62] Pharmacological strategies to decrease excessive blood loss in cardiac surgery:: a meta-analysis of clinically relevant endpoints [J].

Levi, M ;

Cromheecke, ME ;

de Jonge, E ;

Prins, MH ;

de Mol, BJM ;

Briët, E ;

Büller, HR .

LANCET, 1999, 354 (9194) :1940-1947

[63] Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes [J].

Levy, J. . H. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (09) :1875-1878

[64] Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile [J].

Levy, Jerrold H. ;

Fingerhut, Abe ;

Brott, Thomas ;

Langbakke, Irene H. ;

Erhardtsen, Elisabeth ;

Porte, Robert J. .

TRANSFUSION, 2006, 46 (06) :919-933

[65] A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF APROTININ FOR REDUCING BLOOD-LOSS AND THE REQUIREMENT FOR DONOR-BLOOD TRANSFUSION IN PATIENTS UNDERGOING REPEAT CORONARY-ARTERY BYPASS-GRAFTING [J].

LEVY, JH ;

PIFARRE, R ;

SCHAFF, HV ;

HORROW, JC ;

ALBUS, R ;

SPIESS, B ;

ROSENGART, TK ;

MURRAY, J ;

CLARK, RE ;

SMITH, P ;

NADEL, A ;

BONNEY, SL ;

KLEINFIELD, R .

CIRCULATION, 1995, 92 (08) :2236-2244

[66] Inhibition of fibrinolysis by recombinant factor VIIA in plasma from patients with severe hemophilia A [J].

Lisman, T ;

Mosnier, LO ;

Lambert, T ;

Mauser-Bunschoten, EP ;

Meijers, JCM ;

Nieuwenhuis, HK ;

de Groot, PG .

BLOOD, 2002, 99 (01) :175-179

[67] Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation [J].

Lodge, JPA ;

Jonas, S ;

Jones, RM ;

Olausson, M ;

Mir-Pallardo, J ;

Soefelt, S ;

Garcia-Valdecasas, JC ;

McAlister, V ;

Mirza, DF .

LIVER TRANSPLANTATION, 2005, 11 (08) :973-979

[68] Recombinant coagulation factor VIIa in major liver resection -: A randomized, placebo-controlled, double-blind clinical trial [J].

Lodge, JPA ;

Jonas, S ;

Oussoultzoglou, E ;

Malagó, M ;

Jayr, C ;

Cherqui, D ;

Anthuber, M ;

Mirza, DF ;

Kuhlman, L ;

Bechstein, WO ;

Díaz, JCM ;

Tartiere, J ;

Eyraud, D ;

Fridberg, M ;

Erhardtsen, E ;

Mimoz, O .

ANESTHESIOLOGY, 2005, 102 (02) :269-275

[69] The risk associated with aprotinin in cardiac surgery [J].

Mangano, DT ;

Tudor, IC ;

Dietzel, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (04) :353-365

[70]

Mannucci PM, 2007, PLATELETS, 2ND EDITION, P1237, DOI 10.1016/B978-012369367-9/50829-6

← 2 3 4 5 6 7 8 9 10 11 →